ADAM23

Across TCGA pan-cancer cohorts, ADAM23 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ADAM23 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ADAM23 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAM23 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, ESCA, and LUSC are the cancer types where ADAM23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.969	0.824	.006	26	view →
ESCA	DFS	Median	III,IV	0.080	0.442	<.001	12	view →
LUSC	OS	Median	All	0.371	0.824	.002	12	view →
BLCA	OS	Median	III,IV	0.141	0.581	.011	9	view →
STAD	DFS	Median	II,III,IV	1.000	0.376	.023	6	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →
SKCM	DFS	Median	III,IV	0.169	0.653	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ADAM23–UCEC (DFS)

Open the UCEC breakdown →